1401 studies found for:    Open Studies | "Breast Diseases"
Show Display Options
Rank Status Study
21 Not yet recruiting Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Condition: Breast Cancer
Interventions: Drug: Eribulin Mesylate;   Drug: Pembrolizumab
22 Not yet recruiting PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Palbociclib;   Drug: Standard Adjuvant Endocrine Therapy
23 Not yet recruiting A Dose-escalation Study of ARX788, IV Administered in Subjects With Breast Cancer With HER2 Expression
Condition: Breast Neoplasms
Intervention: Drug: ARX788
24 Not yet recruiting Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib
Condition: Triple Negative Breast Cancer
Intervention: Drug: Afatinib
25 Recruiting Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients
Condition: Breast Cancer Metastatic
Interventions: Drug: Everolimus;   Drug: Aromatase Inhibitors
26 Recruiting A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs
Condition: Breast Neoplasms
Interventions: Drug: Epirubicin;   Drug: Docetaxel;   Drug: Trastuzumab;   Drug: Carboplatin
27 Recruiting Monitoring Neoadjuvant Chemotherapy Response in Breast Cancer Patients Using Diffuse Optical Spectroscopic Imaging
Condition: Breast Cancer
Intervention: Device: Diffuse Optical Spectroscopy Imaging (DOSI)
28 Not yet recruiting The Plan and Stand Study: Reducing Sitting Time in Breast Cancer Survivors
Condition: Breast Neoplasms
Interventions: Behavioral: Re-Patterning Sitting Time Group;   Behavioral: Reducing Sitting Time Group;   Behavioral: Usual Care
29 Recruiting Study of Body Composition in Patients Treated by Adjuvant Hormonal Therapy for Breast Cancer (MetaCa2)
Conditions: Hormonal Therapy;   Breast Cancer
Intervention: Other: Body composition measurement
30 Recruiting Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.
Condition: Breast Cancer
Interventions: Drug: metformin;   Drug: Fluoruracil;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: melatonin
31 Recruiting Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: BYl719
32 Recruiting Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer
Condition: Breast Cancer
Intervention:
33 Not yet recruiting A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature
Condition: Metastatic Breast Cancer
Intervention: Drug: rucaparib
34 Not yet recruiting Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Cyclophosphamide;   Other: Function Assessment of Cancer Therapy (FACT) Surveys
35 Not yet recruiting Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
Condition: Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: Drug: Palbociclib;   Drug: Nab-Paclitaxel
36 Not yet recruiting Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients
Condition: Breast Cancer
Interventions: Drug: Nivolumab;   Radiation: Radiation therapy;   Drug: Low dose doxorubicin;   Drug: Cyclophosphamide;   Drug: Cisplatin
37 Not yet recruiting Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
Condition: Advanced Breast Cancer
Interventions: Drug: Palbociclib;   Drug: Letrozole
38 Not yet recruiting Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Pancreatic Adenocarcinoma;   Pancreatic Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Small Cell Lung Carcinoma;   Stage III Pancreatic Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Small Cell Lung Carcinoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Small Cell Lung Carcinoma;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Small Cell Lung Carcinoma;   Stage IVA Pancreatic Cancer;   Stage IVB Pancreatic Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: 18F-Fluoromisonidazole;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Procedure: Positron Emission Tomography
39 Not yet recruiting Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients
Condition: Malignant Neoplasm of Breast
Interventions: Procedure: Pectoral Block 2;   Drug: Bupivacaine 0.25-0.5%
40 Recruiting Initial Assessment of an Internet-based Symptom Management Intervention in Early Stage Breast Cancer
Conditions: Breast Cancer;   Fatigue;   Insomnia;   Pain
Intervention: Behavioral: PROSPECT

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years